Sude Yarar

Dr. Sude Yarar

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SYSude Yarar
Sude Yarar
Panagiotis TsagozisPanagiotis Tsagozis
Panagiotis Tsagozis
Background/Objectives: Soft tissue sarcomas (STSs) are rare tumors arising from mesenchymal tissues, comprising over 100 distinct histological subtypes with varying biological behaviors, metastatic patterns, and treatment responses Despite advances in multimodal therapy, the overall survival of patients with metastatic STS is poor, mainly due to the weak response to conventional chemotherapy based on doxorubicin and ifosfamide. Methods: This review examines the evolution from traditional one-size-fits-all treatments to personalized medicine strategies, primarily focusing on assays based on patient-derived tumor samples, and it highlights their emerging role in guiding personalized treatment decisions and improving clinical outcomes in STS. These approaches, also known as functional precision oncology, are a step closer to the clinical situation as compared to other personalized therapies that rely on the identification of targetable genomic alterations using high-throughput technologies such as whole-genome sequencing, which have thus far failed to show convincing responses in STS treatment. Results: The main functional precision oncology platforms tested in patients with STS are in vitro cell viability tests, organoid cultures, and patient-derived xenografts. Each has advantages and limitations. In this context, in vitro drug sensitivity using cell suspension or organoids has shown a strong correlation with clinical responses. Furthermore, organoids matched the original tumor histology and microenvironment to a satisfactory degree. Establishment of xenografts proved feasible in the majority of patients; the technique could also preserve the tumor architecture and displayed high physiological relevance to the clinical situation. Conclusions: Although a major clinical study directly comparing conventional chemotherapy to personalized treatment guided by functional assays is yet to be published, this approach has gained popularity given the low efficacy of personalized medicine based on genetic alterations. The results thus far show promise for a better outcome for patients with metastatic STS.

21 April 2026 in World Journal of Urology
Verified
Journal Article
Closed access
AAAhmet Baris Aydin
Ahmet Baris Aydin
GGGuven Gunver
Guven Gunver
IGİsMail Taha Gürlek
İsMail Taha Gürlek
SYSude Yarar
Sude Yarar
FÖFaruk Özcan
Faruk Özcan
TTTzevat Tefik
Tzevat Tefik

18 August 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
SYSude Yarar
Sude Yarar
Panagiotis TsagozisPanagiotis Tsagozis
Panagiotis Tsagozis
Background/Objectives: Primary benign and malignant musculoskeletal tumours are generally treated with surgical excision. Metastatic musculoskeletal disease may require both systemic and local treatment. This review focuses on the use of radiofrequency ablation (RFA), cryoablation, cementoplasty, and high-intensity focused ultrasound (HIFU) in primary musculoskeletal tumours and bone and soft-tissue metastases. Methods: We reviewed English-language studies addressing the indications, clinical outcomes, patient selection, and complications of these techniques in patients with primary musculoskeletal tumours or bone and soft-tissue metastases. Results: RFA is the preferred minimally invasive treatment for osteoid osteoma and may be considered for selected small intraosseous tumours. In symptomatic bone metastases, RFA may provide pain relief and can be combined with cementoplasty when structural support is needed. Cryoablation is used selectively for benign, locally aggressive, recurrent, and metastatic tumours, with the advantage of visualizing the ablation zone. Cementoplasty is mainly used to relieve mechanical pain and reinforce weakened bone. HIFU has been studied mainly for pain palliation in bone metastases, while evidence in primary malignant tumours remains limited. Conclusions: Image-guided interventions can complement surgery and radiotherapy in selected patients. Treatment choice depends on tumour type, location, treatment intent, skeletal stability, and proximity to critical structures.